Literature DB >> 11589915

Activation of complement and contact system in Alzheimer's disease.

L Bergamaschini1, C Donarini, G Gobbo, L Parnetti, V Gallai.   

Abstract

beta-Amyloid protein (betaA) has been implicated in the pathogenesis of Alzheimer's disease (AD) because of its neurotoxicity and ability to trigger a local inflammatory response. Although assembly of betaA in particular aggregates seems to be crucial event in AD pathogenesis, soluble, non-fibrillar betaA may also be involved. Non-fibrillar betaA1-42, and truncated peptide 1-28, induced dose-dependent activation of C4 sparing C3. The mechanism of C4 activation was not dependent on C1q, because non-fibrillar betaA can still activate C4 in plasma genetically deficient in C1q. A C1q independent mechanism of complement classical pathway activation could be via the activation of contact/kinin system. The possible involvement of contact system in AD is suggested by the finding that this system is massively activated in CSF of AD patients. The mechanism of activation of contact system could be the result of an anionic interaction of residues within the region 1-11 of betaA1-42 with factor XII, and of kallikrein generation. Concomitant incubation of a small cationic peptide (lysine4) with betaA abrogated its ability to trigger the cleavage of high molecular weight kininogen. In vivo, prevention of contact system activation beside the reduction of kallikrein generation, can also decrease the activation of complement system and the release of interleukin-6, both factors being considered to play an important role in the inflammatory reactions in AD brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589915     DOI: 10.1016/s0047-6374(01)00311-6

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  14 in total

1.  Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis.

Authors:  Milenka Sain; Vedran Kovacic; Josipa Radic; Dragan Ljutic; Ivo Jelicic
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

2.  Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability.

Authors:  Georgette L Suidan; Pradeep K Singh; Sunita Patel-Hett; Zu-Lin Chen; Dmitri Volfson; Hitomi Yamamoto-Imoto; Erin H Norris; Robert D Bell; Sidney Strickland
Journal:  Blood Adv       Date:  2018-05-08

Review 3.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

4.  Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease.

Authors:  Jonny Daborg; Ulf Andreasson; Marcela Pekna; Ronald Lautner; Eric Hanse; Lennart Minthon; Kaj Blennow; Oskar Hansson; Henrik Zetterberg
Journal:  J Neural Transm (Vienna)       Date:  2012-04-10       Impact factor: 3.575

5.  The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.

Authors:  D Zamolodchikov; T Renné; S Strickland
Journal:  J Thromb Haemost       Date:  2016-02-29       Impact factor: 5.824

6.  Relationship between the gene polymorphisms of kallikrein-kinin system and Alzheimer's disease in a Hunan Han Chinese population.

Authors:  Yanyao Deng; Deren Hou; Mi Tian; Wei Li; Xialu Feng; Zhuling Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

7.  Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.

Authors:  Sarah K Baker; Zu-Lin Chen; Erin H Norris; Alexey S Revenko; A Robert MacLeod; Sidney Strickland
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-25       Impact factor: 11.205

8.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

9.  Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Authors:  Richard J Perrin; Rebecca Craig-Schapiro; James P Malone; Aarti R Shah; Petra Gilmore; Alan E Davis; Catherine M Roe; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Jeffrey A Kaye; John C Morris; David M Holtzman; R Reid Townsend; Anne M Fagan
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.